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In order to manage the COVID-19 systemic inflammatory response, it is important to identify
clinicopathological characteristics across multiple cohorts.
Methods
The aim of the present study was to compare the 4C mortality score, other measures of the
systemic inflammatory response and clinicopathological characteristics in two consecutive
cohorts of patients on admission with COVID-19. Electronic patient records for 2 consecu-
tive cohorts of patients admitted to two urban teaching hospitals with COVID-19 during two
7-week periods of the COVID-19 pandemic in Glasgow, U.K. (cohort 1: 17/3/2020–1/5/
2020) and (cohort 2: 18/5/2020–6/7/2020) were examined for routine clinical, laboratory and
clinical outcome data.
Results
Compared with cohort 1, cohort 2 were older (p<0.001), more likely to be female (p<0.05)
and have less independent living circumstances (p<0.001). More patients in cohort 2 were
PCR positive, CXR negative (both p<0.001) and had low serum albumin concentrations
(p<0.001). 30-day mortality was similar between both cohorts (23% and 22%). In cohort 2,
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age >70 (p<0.05), male gender (p<0.05), COPD (p<0.05), cognitive impairment (p<0.05),
frailty (p<0.001), delirium (p = 0.001), CRP>150mg/L (p<0.05), albumin <30 g/L (p<0.01),
elevated perioperative Glasgow Prognostic Score (p<0.05), elevated neutrophil-lymphocyte
ratio (p<0.001), low haematocrit (p<0.01), elevated PT (p<0.05), sodium <133 mmol/L
(p<0.01) elevated urea (p<0.001), creatinine (p<0.001), glucose (p<0.05) and lactate
(p<0.001) and the 4C score (p<0.001) were associated with 30-day mortality. In multivariate
analysis, greater frailty (CFS>3) (OR 11.3, 95% C.I. 2.3–96.7, p<0.05), low albumin (<30g/
L) (OR 2.5, 95% C.I. 1.0–6.2, p<0.05), high NLR (�3) (OR 2.2, 95% C.I. 1.5–4.5, p<0.05)
and the 4C score (OR 2.4, 95% C.I. 1.0–5.6, p<0.05) remained independently associated
with 30-day mortality.
Conclusion
In addition to the 4C mortality score, frailty score and a low albumin were strongly indepen-





The number of people worldwide who are known to have been infected with COVID-19
(SARS-CoV-2 infection) increased from 30 million to 84 million in a twelve week period
between September 2020 and January 2021, and the number who have died has almost dou-
bled (1 million to 1.8 million) [1]. The severity of this viral disease for an individual is associ-
ated with a widespread perturbation of immune, physiological and metabolic parameters [2,
3]. These whole-body changes are characteristic of a systemic inflammatory response to tissue
injury. Indeed, measures of this systemic inflammatory response have been shown to have
prognostic value [4–6]. In particular, the 4C mortality score was developed in more than
55,000 patients with COVID-19 and measured the systemic inflammatory response using C-
reactive protein [6]. Other measures of the systemic inflammatory response such as the neutro-
phil lymphocyte ratio (NLR) have also been shown to have prognostic value [7]. Moreover, the
systemic inflammatory response has been shown to be a useful therapeutic target in patients
with COVID-19 [8–10]. However, to date, as there have been variations in the assessment of
the systemic inflammatory response, other important factors may remain to be identified.
Experience in consecutive cohorts also remains limited.
The aim of the present study was to compare the 4C mortality score, other measures of the
systemic inflammatory response and clinicopathological characteristics in two consecutive
cohorts of patients on admission with COVID-19.
Patients and methods
Electronic patient records for patients who were admitted to two large city teaching hospitals
(Glasgow Royal Infirmary (GRI) and the Queen Elizabeth University Hospital (QEUH), Glas-
gow, U.K.), for two consecutive cohorts, cohort 1 (n = 243, 1/4/2020-18/5/2020) [5] and cohort
2 (n = 261, 18/5/2020-6/7/2020) were examined for routine clinical, laboratory and clinical
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outcome data. These teaching hospitals serve urban populations with a high burden of socio-
economic deprivation and offer the full spectrum of adult acute receiving specialties to patients
over 16 years old. In line with NHS policy, the NHS Greater Glasgow and Clyde Caldicott
guardian approved this study. The study protocol (GN20AE307) was approved by the North
West England–Preston research ethics committee (20/NW/0336) and registered with clinical-
trials.gov (NCT04484545). The research ethics committee waived requirement for informed
consent and data were gathered from electronic patient records between April 2020 and
August 2020.
Details of the recruitment of patients between 1/4/2020-18/5/2020 for cohort 1 have been
previously described [5]. In patients admitted to hospital between 18/5/2020-6/7/2020, age,
sex, BMI and polymerase chain reaction (PCR) confirmed evidence of COVID-19 infection at
time of discharge or death certification were considered minimal criteria for inclusion in
cohort 2.
As per routine clinical practice in the Emergency Department (ED) and Acute Assessment
Unit (AAU) in both hospitals, patients were scored on the National Early Warning Score
(NEWS) at presentation to triage. NEWS is a validated score of severity of physiological
derangement that allocates a score (0–3) to six clinical parameters (pulse rate, blood pressure,
respiratory rate, oxygen saturations, requirement for supplemental oxygen and level of respon-
siveness (alert (A), responding to verbal (V), painful (P) stimuli and unresponsive (U) AVPU
scale)) [11]. NEWS determines the triage category and level of immediate treatment that is
required at the time of presentation, and the interval to re-administering the NEWS scoring
tool according to the score achieved (i.e. the severity of physiological derangement). NEWS
>4 and>7 are considered to indicate moderately severe and severe physiological derangement
respectively.
The 4C Mortality Score is a validated prognostic score that predicts in-hospital mortality
among patients with COVID-19 who are admitted to a general hospital setting in the U.K. [6].
It includes eight variables that are readily available at initial hospital assessment: age, sex, num-
ber of comorbidities, respiratory rate, peripheral oxygen saturation, level of consciousness,
urea level, and C-reactive protein (score range 0–21 points) (see Table 1).
In the present study, age was grouped as less than 40 years, 40–49 years, 50–59 years, 60–69
years, 70–79 years and 80 years and older. Age categories were further simplified to</� 70
years. Social deprivation was defined by the Scottish Indices of Multiple Deprivation 2019
based on individual home postcode. Ethnicity was classified as White, Mixed, Asian, Black, or
other ethnic group.
Frailty was assessed using the Clinical Frailty Scale (CFS) [12, 13]. The CFS is a validated
measure of clinical frailty that has been shown to have prognostic value [13]. The CFS includes
items such as comorbidity, cognitive impairment and disability while also incorporating func-
tional interpretation of physical frailty according to level of dependence in living circum-
stances [12]. In the present study, living circumstances were classified as: independent; living
at home with support from family member / paid care assistant or sheltered accommodation;
care home; or dependent living in a nursing home.
Admission serum C-reactive protein (CRP), albumin concentrations and differential blood
cell counts were categorised using local reference intervals. Neutrophil-lymphocyte ratio
(NLR) and the peri-operative Glasgow Prognostic Score (poGPS) were calculated as outlined
in Tables 2 and 3 [14–16]. The NLR and poGPS are validated prognostic scoring systems that
have been used in a variety of clinical settings. They both utilise two components, neutrophils/
lymphocytes and C-reactive protein/ albumin respectively, that are routinely measured in
patients admitted to the general hospital setting. For this study, each scoring system had 3 divi-
sions indicating mild, moderate and severe systemic inflammatory response respectively [17].
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Statistical analysis
Demographical and clinicopathological data were presented as categorical variables using rec-
ognised clinical thresholds. These variables were analysed using χ2 test for linear-by-linear
association, or χ2 test for 2-by-2 tables.
Table 2. Calculation of the neutrophil lymphocyte ratio (NLR).
Neutrophil Lymphocyte Ratio (NLR): Ratio SIRS Severity
Neutrophil count: lymphocyte count <3 Mild
Neutrophil count: lymphocyte count 3–5 Moderate
Neutrophil count: lymphocyte count >5 Severe
https://doi.org/10.1371/journal.pone.0251924.t002
Table 1. Final 4C mortality score for in-hospital mortality in patients with COVID-19. Prognostic index derived
from penalised logistic regression (LASSO) model [6].
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� Comorbidities were defined by using Charlson comorbidity index, with the addition of clinician defined obesity
https://doi.org/10.1371/journal.pone.0251924.t001
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Associations between demographical, clinicopathological characteristics and mortality
were analysed using univariate and a multivariate backward conditional approach. A p< 0.05
was applied to inclusion at each step in the multivariate analysis.
A convenience sampling strategy was adopted based on the patients admitted during the
study period; therefore, a formal sample size calculation was not performed. Missing data were
excluded from analysis on a variable-by-variable basis. Two-tailed p values <0.05 were consid-
ered statistically significant. Statistical analysis was performed using SPSS software version
27.0. (SPSS Inc., Chicago, IL, USA).
Results
Details of the recruitment of patients for cohort 1 (n = 243) have been previously described
[5]. In cohort 2, of the 356 patients who were confirmed to have COVID-19 infection by PCR
test, 278 patients fulfilled the criteria for inclusion with age, sex, BMI. Seventeen patients were
re-admitted and these were excluded from the analysis at second admission leaving 261
patients to be included in the analysis.
Comparison of the demographical and clinicopathological characteristics of the two cohorts
are shown in Table 4. Compared with cohort 1, cohort 2 were older (p<0.001), more likely to
be female (p<0.05) and have less independent living circumstances (p<0.001). With reference
to previous medical history, compared with cohort 1, cohort 2 had hypertension and heart fail-
ure (both p<0.05), had chronic renal failure (p<0.001), had cognitive impairment and previ-
ous delirium (both p<0.01), were less frail (p<0.001) and had less asthma (p<0.01). With
reference to diagnostic criteria, compared with cohort 1, cohort 2 were more likely to be PCR
positive and CXR negative (both p<0.001). With reference to laboratory results, compared
with cohort 1, cohort 2 had low albumin (p<0.001), low haemoglobin (p<0.001), low haema-
tocrit (p<0.05), lower MCV (0.05), abnormal sodium (p<0.01), elevated creatinine (p<0.01),
elevated alkaline phosphatase (p<0.001). 30-day mortality was similar between the cohorts
(23% and 22%).
The relationship between demographic and clinicopathological characteristics and 30-day
mortality in cohort 2 is shown in Table 5. In cohort 2, age�70 (p<0.05), male gender
(p<0.05), COPD (p<0.05), cognitive impairment (p<0.05), frailty (p<0.001), delirium
(p = 0.001), CRP�150mg/L (p<0.05), albumin<30 g/L (p<0.01), elevated perioperative Glas-
gow Prognostic Score (p<0.05), elevated neutrophil-lymphocyte ratio (p<0.001), low haema-
tocrit (p<0.01), elevated PT (p<0.05), sodium <133 mmol/L (p<0.01) elevated urea
(p<0.001), creatinine (p<0.001), glucose (p<0.05) and lactate (p<0.001) and the 4C score
(p<0.001) were associated with 30-day mortality.
In the combined cohorts (n = 504), there was no association between serum sodium con-
centrations and use of medications such as proton pump inhibitors (p = 0.119), angiotensin
converting enzyme inhibitors (ACEi’s) (p = 0.608) or diuretics (p = 0.675).
To determine which admission parameters were independently associated with 30-day
mortality, those factors identified in Table 5 as significant and not in the 4C mortality score
Table 3. Peri-operative Glasgow Prognostic Score (poGPS).
Peri-operative Glasgow Prognostic Score (poGPS) Score SIRS Severity
C-reactive protein� 150mg/l and Albumin�25 g/l 0 Mild
C-reactive protein > 150mg/l and Albumin�25 g/l 1 Moderate
C-reactive protein� 150mg/l and Albumin <25 g/l 1 Moderate
C-reactive protein > 150mg/l and Albumin <25 g/l 2 Severe
https://doi.org/10.1371/journal.pone.0251924.t003
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Table 4. Comparison of the demographical and clinicopathological characteristics of 2 consecutive cohorts patients admitted to hospital with COVID-19.
Cohort 1 (n = 243) Cohort 2 (n = 261) p-value
n % n %
30-days post admission (alive /dead) 188/55 77/23 203/58 78/22 0.912
Age (</�70 years) 157/86 65/35 89/172 34/66 <0.001
Sex (male/female) 133/110 55/45 119/142 46/54 0.041
BMI (<20;�20–29;�30 kg/m2) 18/119/106 7/44/49 42/139/80 16/53/31 0.475
SIMD (1 (most)– 6 (least) deprived) 124/35/25/26/22/11 51/14/10/11/9/5 98/49/27/29/32/20 38/19/11/11/13/8 0.011
Ethnicity (1–5) 209/0/7/2/5 93/0/4/1/2 239/1/20/1/0 91/0.4/8/0.4/0 0.818
Living circumstances (0–5) 206/16/15/4/2 84/7/6/2/1 178/18/24/41/0 68/7/9/16 <0.001
Past Medical History
Hypertension (y/n) 96/147 (40/60) 39/61 129/132 49/51 0.025
Heart failure (y/n) 23/220 10/90 42/219 16/84 0.027
T1DM (y/n) 2/241 1/99 2/259 1/99 0.943
T2DM (y/n) 58/185 24/76 61/199 24/76 0.915
Chronic renal failure (y/n) 29/214 12/88 62/199 24/76 0.001
Cognitive impairment (y/n) 31/212 13/87 85/176 33/67 <0.001
Previous delirium (y/n) 16/225 7/93 41/219 16/84 0.001
Clinical frailty score (�/> 3) 134/109 55/45 75/185 71/29 <0.001
COPD (y/n) 41/202 17/83 47/214 18/82 0.738
Smoker (never/ex/active) 82/70/20 48/42/10 24/27/1 56/38/6 0.428
Alcohol excess (y/n) 33/210 14/86 30/231 12/88 0.480
Liver disease (y/n) 20/223 8/92 12/249 5/95 0.095
Hep C (never/previous/active) 237/3/2 98/1/1 260/0/1 99/0.5/0 0.166
Active cancer (y/n) 11/232 5/95 16/245 6/94 0.425
Asthma (y/n) 47/196 20/80 24/237 9/91 0.001
Diagnostic criteria
PCR positive/Clinical Dx. /Radiological Dx 120/8/115 50/3/47 261/0/0 100/0/0 <0.001
PCR negative/indeterminate/positive 49/54/136 20/22/58 0/24/237 0/8/92 <0.001
CXR negative/positive 101/138 42/58 148/98 60/40 <0.001
Physiology at presentation
NEWS (� / > 4) 92/149 38/62 126/123 51/49 0.006
Delirium (y/n) 26/211 11/89 54/179 23/77 <0.001
Laboratory results at presentation
CRP (<150 /�150 mg/L) 182/60 75/25 211/49 81/19 0.107
Albumin (�35/<35 g/L) 104/135 43/57 75/179 30/70 <0.001
poGPS (0/1/2) 176/55/7 72/23/3 192/53/8 76/21/3 0.711
WCC (< 4.5 /�4.5 - �11.0 / >11.0 x 109/L) 36/165/41 68/15/17 44/160/53 62/17/21 0.176
Neutrophils (< /� 7.5 x 109/L) 183/59 76/24 185/71 72/28 0.395
Lymphocytes (� / < 1.5 x 109/L) 64/176 26/74 62/162 24/76 0.415
NLR (<3/ 3–5 /� 5) 52/58/130 22/24/54 60/63/133 23/25/52 0.587
Hb (�/<12.0 g/dL) 195/46 81/19 163/93 64/36 <0.001
Hct (male�/< 0.40) (female�/< 0.37) L/L 169/73 70/30 153/104 60/40 0.016
MCV (<80/�80 - <99/� 99 fl) 6/218/16 3/91/7 5/207/45 2/80/18 0.011
Platelets (< 150/�150 - <400/>400x109) 16/188/9 78/18/4 33/197/25 13/77/10 0.103
Sodium (<133/�133-�146/>146 mmol/L) 28/210/5 12/86/4 41/204/16 16/78/6 0.006
Potassium (<3.5/�3.5-�5.5/>5.5 mmol/L) 22/192/2 10/89/1 29/206/7 12/85/3 0.135
Mg (�/< 0.75 mmol/L) 41/88 69/31 38/30 56/44 0.063
Urea (�/> 7.5 mmol/L) 162/81 67/33 150/111 58/42 0.034
(Continued)
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were also entered into a binary logistic regression analysis (Table 6). In this multivariate analy-
sis, only greater frailty (CFS>3) (OR 11.3, 95% C.I. 2.3–96.7, p<0.05), low albumin (<30g/L)
(OR 2.5, 95% C.I. 1.0–6.2, p<0.05) and high NLR (�3) (OR 2.2, 95% C.I. 1.5–4.5, p<0.05) and
the 4C score (OR 2.4, 95% C.I. 1.0–5.6, p<0.05) remained independently associated with
30-day mortality.
Discussion
The results of the present study show that, in 2 consecutive cohorts, there was a variation in
the admission demographic and clinicopathological characteristics. In particular, the latter
cohort were older, had more cardiovascular and renal disease and greater derangement of
their laboratory data. Despite this, 30-day mortality was similar between the cohorts. In both
cohorts the 4C score, which incorporates age, sex, comorbidity, respiratory, renal and brain
function and a measure of the activation of the systemic inflammatory response, had prognos-
tic value. In addition, when compared directly with the 4C mortality score a number of other
factors had independent prognostic value, in particular clinical frailty and a low albumin.
Taken together, the present results would suggest that the relationship between clinicopatho-
logical factors and short-term mortality in patients with COVID-19 may vary with time. Also,
that there are other important factors in short term mortality of patients with COVID-19, not
captured by the 4C mortality score and such factors may improve the prognostic value of the
4C score. Therefore, there is a need for further work to determine independent prognostic
value of clinicopathological factors in patients presenting with COVID-19.
Dysnatraemia (both hyponatremia and hypernatremia) are known to be associated with
mortality and sepsis, but only hyponatremia is usually associated with intensive therapy.
Admittance hyponatraemia is recognised to be associated with increased mortality. Further-
more, hyponatremia has been reported to be a risk factor for infection, specifically for Staphy-
lococcus aureus bacteremia [18]. In the present study, the majority of patients had haematocrit
concentrations within normal parameters and there was no significant association between
Table 4. (Continued)
Cohort 1 (n = 243) Cohort 2 (n = 261) p-value
n % n %
Creatinine (�/>130 umol/L) 218/25 90/10 208/53 80/20 0.002
AST (�/ > 40 IU) 131/78 63/37 153/74 67/33 0.302
ALT (�/ > 56 IU) 203/35 85/15 211/43 83/17 0.500
AST: ALT </� 2 180/29 86/14 183/43 81/19 0.149
ALP (�/ > 130 IU) 221/18 93/7 198/56 78/22 <0.001
Bilirubin (�/ > 17 mmol/L) 213/26 89/11 217/37 85/15 0.221
Glucose (�/ > 7 mmol/L) 123/81 60/40 124/58 68/32 0.110
Lactate (</� 2 mmol/L) 60/35 64/36 60/45 57/43 0.299
HCO3 (� / < 22 mmol/L) 46/12 80/20 66/33 67/33 0.092
PT (� / > 13 seconds) 125/70 64/36 94/55 63/37 0.846
APPT (� / > 38 seconds) 177/12 94/6 126/22 85/15 0.010
Alive/Dead at 30-days 188/55 77/23 203/58 78/22 0.912
Level of care (ward/HDU/ITU)
Initial level of care 199/15/8 89/7/4 236/13/6 93/5/2 0.261
Max level of care 159/38/25 72/17/11 228/13/14 89/5/6 <0.001
poGPS: Peri-operative Glasgow Prognostic Score; NLR: neutrophil lymphocyte ratio
https://doi.org/10.1371/journal.pone.0251924.t004
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Table 5. Univariate analysis of demographical, clinicopathological characteristics and 30-day mortality in the sec-
ond cohort of patients admitted with confirmed COVID-19 (n = 261).
Alive (n = 203) Dead (n = 58) p-value
Age (</�70 years) 77/126 12/46 0.015
Sex (male/female) 85/118 34/24 0.024
BMI (<20;�20–29;�30 kg/m2) 27/104/72 15/35/8 0.756
SIMD (1 (most)– 6 (least) deprived) 80/36/21/18/29/15 18/13/6/11/3/5 0.777
Ethnicity (1–5) 185/1/16/1/0 54/0/4/0/0 0.639
Living circumstances (0–4) 146/14/16/27 32/4/8/14 0.010
Past Medical History
Hypertension (y/n) 96/107 33/25 0.198
Heart failure (y/n) 31/172 11/47 0.500
T1DM (y/n) 1/202 1/57 0.344
T2DM (y/n) 43/159 18/40 0.123
Chronic renal failure (y/n) 43/160 19/39 0.068
Cognitive impairment (y/n) 59/144 26/32 0.024
Previous delirium (y/n) 31/171 10/48 0.728
Clinical frailty score (�/> 3) 130/72 55/3 <0.001
COPD (y/n) 32/171 15/43 0.078
Smoker (never/ex/active) 119/71/13 27/29/2 0.312
Alcohol excess (y/n) 25/178 5/53 0.437
Liver disease (y/n) 9/194 3/55 0.813
Hep C (never/previous/active) 203/0/0 57/0/1 0.061
Active cancer (y/n) 11/192 5/53 0.371
Asthma (y/n) 22/181 2/56 0.086
Diagnostic radiology
CXR negative/positive 119/72 26/29 0.202
Physiology at presentation
NEWS (� / > 4) 103/90 23/33 0.106
Delirium (y/n) 149/33 30/21 0.001
Laboratory results at presentation
CRP (< / �150 mg/L) 170/32 41/17 0.021
Albumin (�/<30 g/L) 52/146 30/26 0.004
poGPS (0/1/2) 156/35/6 36/18/2 0.047
WCC (< 4.5 /�4.5 -�11.0 / >11.0 x 109/L) 38/127/34 6/33/19 0.062
Neutrophils (< /� 7.5 x 109/L) 155/43 30/28 <0.001
Lymphocytes (� / < 1.5 x 109/L) 55/142 7/50 0.016
NLR (<3/ 3–5 /� 5) 56/58/84 4/5/49 <0.001
Hb (�/<12.0 g/dL) 125/73 38/20 0.740
Hct (male�/< 0.40) (female�/< 0.37) L/L 122/77 31/27 0.284
MCV (<80/�80 - <99/� 99 fl) 5/162/32 0/45/13 0.848
Platelets (< 150/�150 x109) 22/175 11/47 0.121
Sodium (<133/�133- �146/>146 mmol/L) 32/164/7 9/40/9 0.005
Potassium (<3.5/�3.5-�5.5/>5.5 mmol/L) 44/160/4 7/46/3 0.304
Mg (�/< 0.75 mmol/L) 71/35 25/8 0.343
Urea (�/> 7.5 mmol/L) 133/70 17/41 <0.001
Creatinine (�/>130 umol/L) 177/26 31/27 <0.001
AST (�/ > 40 IU) 121/54 32/20 0.305
ALT (�/ > 56 IU) 160/38 51/5 0.071
(Continued)
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haematocrit and serum sodium concentrations, however data relating to the presence of bacte-
rial supra-infections was not gathered in the present study. Also, in relation to dysnatraemia, it
has been reported that pro-inflammatory cytokines particularly IL-1b and IL-6 can stimulate
hypothalamic Arginine Vasopressin secretion and that circulating IL-6 concentrations are
inversely associated with Na concentrations in patients with COVID-19 sepsis [19]. In the
present study IL-6 concentrations were not measured and data relating to treatment with spe-
cific anti-IL-6 agents was not collected. However, data was collected on proton pump inhibi-
tors (PPi’s), angiotensin converting enzyme inhibitors (ACEi’s), diuretics, NSAIDs, Ca2+
blockers, immuno-suppressants (including steroids) prior to presentation and in the com-
bined cohorts (n = 504), there was no association between serum sodium concentrations and
use of medications such as PPi’s, ACEi’s or diuretics.
In the present study admittance hypoalbuminaemia was a predictive factor for COVID-19
outcomes. The results of the present study are also consistent with a meta-analysis of sixty-
seven studies in 19,760 COVID-19 patients (6,141 with severe disease or poor outcome)
reported by Paliogiannis and co-workers that lower serum albumin concentrations were sig-
nificantly associated with disease severity and adverse outcomes in COVID-19 patients [20].
As such, they suggest that serum albumin concentrations might assist with early risk stratifica-
tion and selection of appropriate care pathways for patients with COVID-19 infection. Indeed,
it is recognised that as part of the systemic inflammatory response there is escape of serum
albumin into the interstitial space due to increased capillary permeability resulting in lower
circulating albumin concentrations. Therefore, it may be concluded that hypoalbuminaemia is
a useful therapeutic target and that albumin supplementation would be an effective therapeutic
Table 5. (Continued)
Alive (n = 203) Dead (n = 58) p-value
AST: ALT </� 2 145/29 38/14 0.099
ALP (�/ > 130 IU) 158/40 40/16 0.183
Bilirubin (�/ > 17 mmol/L) 173/25 44/12 0.100
Glucose (�/ > 7 mmol/L) 101/37 23/21 0.010
Lactate (</� 2 mmol/L) 50/23 10/22 <0.001
HCO3 (� / < 22 mmol/L) 52/20 14/13 0.057
PT (� / > 13 seconds) 78/36 16/19 0.015
APPT (� / > 38 seconds) 95/17 31/5 0.850
4C score (0 - <4 /�4 - <9 /�9 - <15 / �15) 26/65/84/8 1/7/32/13 <0.001
https://doi.org/10.1371/journal.pone.0251924.t005
Table 6. Binary logistic regression analysis of demographical, clinicopathological characteristics and 30-day mortality in the second cohort of patients admitted
with confirmed COVID-19 (n = 203).
Alive (n = 125) Dead (n = 38) p-value ).R. 95% CI p-value
Clinical frailty score (�/> 3) 79/63 12/49 <0.001 11.3 1.3–96.7 0.027
Albumin (�/<30 g/L) 119/23 39/22 0.002 2.5 1.0–6.2 0.045
NLR (<3/�3 - <5/� 5) 28/37/77 3/8/50 <0.001 2.2 1.0–4.5 0.040
Hct (male�/< 0.40) (female�/< 0.37) L/L 106/36 35/26 0.015 0.554
Sodium (<133/�133 -�146/>146 mmol/L) 15/123/4 12/41/8 <0.001 0.321
Glucose (�/ > 7 mmol/L) 80/49 24/30 0.029 0.076
4C score (0 - <4 /�4 - <9 /�9 - <15 /�15) 19/56/50/6 0/6/38/14 <0.001 2.4 1.0–5.6 0.049
Hct: Haematocrit
https://doi.org/10.1371/journal.pone.0251924.t006
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strategy. However, there are parallels with patients who are critically-ill secondary to other
infections and albumin supplementation has not been associated with improved clinical out-
comes [21].
In the present study, the finding that CFS>3 was independently associated with eleven
times higher 30-day mortality in patients admitted to hospital with COVID-19 SIRS is consis-
tent with a recently published meta-analysis by the Geriatric Medicine Collaborative. In their
meta-analysis of data from 5,711 patients admitted to hospital with COVID-19 SIRS, the Geri-
atric Medicine Collaborative report that very high frailty scores (CFS>8) (‘Dependent’ and
‘Bed-bound’) was independently associated with 30-day mortality when compared to non-frail
patients (CFS<3) (CFS 8 vs 1–3: HR 3.03, CI 2.29–4.00) [22]. The findings of the present study
may offer a valuable insight in this context as it includes patients who are classified in the mod-
erate frailty range (CFS4-6).
The basis of the strong prognostic value of the clinical frailty scale and low albumin, inde-
pendent of the 4C mortality score in these patients, is not clear. However, COVID-19 patients
with a clinical frailty score >3 may be considered vulnerable and frail and this entity (the abil-
ity to care for themselves and its relationship with mortality) may not be captured directly by
the 4C score. In particular, the present results may indicate that having COVID-19 induced
cytokine storm in a frail patient is a life threatening event [23]. Similarly, with reference to a
low serum albumin concentration, a cytokine storm would increase the likelihood of mortality.
In the case of a low albumin it is clear that this may reflect both an ongoing systemic inflam-
matory response and also poor nutritional status [24]. It may be that the strong prognostic
value of frailty also reflects poor nutritional status since a systemic inflammatory response
occurring against a background of low metabolic reserves is likely to lead to cellular and organ
dysfunction. If this was the case, then it might be expected that frail and hypoalbuminaemic
patients would benefit most from treatment with anti-inflammatory agents and nutritional
supplementation. Therefore, it may be important to also consider nutritional risk in patients
with COVID-19. Irrespective, it would be important to consider frailty and a low albumin in
the assessment of patients with COVID-19 [25].
To date, in patients with COVID-19, there has been a great deal of focus on the virus itself.
However, it is clear from the prognostic value of host physiology and the host systemic inflam-
matory response in the 4C work [6] and in the efficacy of dexamethasone treatment [13] that
host factors are of considerable importance in outcome of patients with COVID-19. From the
present results it is also clear that frailty and nutritional status are important characteristics to
be taken into the “staging” of patients presenting with COVID-19.
Limitations
The present study has a number of limitations. The sample size is relatively small and therefore
subject to limitations such as sample bias. However, the clinicopathological data collected was
comprehensive across two cohorts, included factors validated in large cohorts of patients with
COVID-19 and therefore allowed direct comparison of these factors.
In the present study, two cohorts of patients with COVID-19 infection were studied, reflect-
ing the rapidly evolving clinical reality of presentation in the early stages of the pandemic. For
example, PCR testing was not as readily available in the first cohort and clinicians were
required to make COVID-19 diagnosis based on WHO and Scottish Department of Health cri-
teria. Therefore, it is perhaps not surprising that there were a number of differences between
the cohorts. However, this is likely to be an issue in many of the reports of clinicopathological
factors and clinical outcomes in patients with COVID-19.
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Conclusion
In the two consecutive cohorts there were variations in a number of clinicopathological char-
acteristics despite similar mortality. In these two cohorts, in addition to the 4C mortality score,
NLR�3, clinical frailty score >3 and low serum albumin concentration (<30 g/L) were inde-
pendently associated with 30-day mortality in patients admitted to hospital with COVID-19
infection.
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